{"doi":"10.3390/curroncol32100541","title":"Phase Ib/II Study of Pamiparib Plus Radiation Therapy and/or Temozolomide in Adult Patients with Treatment-Naïve or Recurrent/Refractory Glioblastoma","abstract":"Pamiparib, a small-molecule poly (ADP-ribose) polymerase (PARP) 1/2 inhibitor, demonstrates strong PARP-DNA complex trapping, antitumor activity, and blood–brain barrier penetration. This phase Ib/II dose-escalation study (NCT03150862) investigated pamiparib’s tolerability/safety and efficacy when combined with radiotherapy and/or low-dose temozolomide (TMZ) in patients with treatment-naïve (Arms A and B) and recurrent/refractory (Arm C) glioblastoma. The recommended phase II dose for Arm A was pamiparib 60 mg twice daily (BID) for 6 weeks with 6–7 weeks radiotherapy; the recommended dose for Arm C was pamiparib 60 mg BID plus 60 mg TMZ (days 1–7; 28-day cycle). The Arm B escalation cohort completed enrollment; the expansion cohort was not opened. Grade ≥3 treatment-emergent adverse events (TEAEs)/serious TEAEs were observed in 55.0%/36.7% (Arm A), 44.4%/22.2% (Arm B), and 66.0%/38.3% (Arm C) of patients. Disease control and objective response rates were 67.9% and 11.3%, respectively, for treatment-naïve patients in the dose-escalation and -expansion studies, and 40.9% and 13.6%, respectively, for recurrent/refractory patients. Median overall survival for treatment-naïve MGMT unmethylated patients was 12.8 months and 7.3 months for recurrent/refractory MGMT methylated and unmethylated patients. Pamiparib with radiotherapy and/or low-dose TMZ was tolerable for treatment-naïve or recurrent/refractory glioblastoma. Treatment-emergent cytopenia was manageable and reversible with dose reductions/interruptions. Combination regimens demonstrated antitumor activity.","journal":"Current Oncology","year":2025,"id":524546,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9525,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1398058,"name":"Kent C. Shih","orcid":"0000-0002-6718-6116","position":1,"is_corresponding":false},{"id":456433,"name":"Pierre Giglio","orcid":"0000-0001-5165-0984","position":2,"is_corresponding":false},{"id":69888,"name":"Howard Colman","orcid":"0000-0002-4027-7317","position":3,"is_corresponding":false},{"id":25299,"name":"Patrick Y. Wen","orcid":"0000-0002-0774-7700","position":4,"is_corresponding":false},{"id":225598,"name":"Jian Campian","orcid":"0000-0002-5317-8481","position":5,"is_corresponding":false},{"id":88539,"name":"Nicholas Butowski","orcid":"0000-0001-5162-2406","position":6,"is_corresponding":false},{"id":247467,"name":"Timothy F. Cloughesy","orcid":"0000-0002-8656-7483","position":7,"is_corresponding":false},{"id":1398598,"name":"Zhaoyin Zhu","orcid":null,"position":8,"is_corresponding":false},{"id":1398599,"name":"Vitaliy Gisin","orcid":null,"position":9,"is_corresponding":false},{"id":1015081,"name":"Michael Badruddoja","orcid":null,"position":10,"is_corresponding":false},{"id":281415,"name":"Anna F. Piotrowski","orcid":"0000-0003-0058-8476","position":0,"is_corresponding":true}],"reference_count":46,"raw_metadata":null,"created_at":"2026-07-19T02:50:12.083054Z","pmid":"41149461","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}